Rachel Croyle, Claire Feller, Cristina Flamand De Los Reyes, Catherine Martini, Isha Mishra, Jordan Terschluse
Download Project (5.9 MB)
Glioma are brain tumors with very poor prognosis. The standard of care is surgery followed by radio- and chemo/immuno-therapy, or combinations thereof, however, healthy cells are affected as well as tumorous cells and all patients eventually die. Thus, there is a need to test if recently approved drugs can inhibit the growth and progression of this tumor. We have developed a Drosophila glioma model based on the two genetic/ oncogenic pathways known to be most frequently activated in patients viz., the Ras/MAPK pathway and the PI3K pathway. We designed a chemical screen involving drugs targeting Tyrosine kinases (Selleck Biochem Chemical library) – key enzymes that are activated by oncogenic pathways. The chemical screen involves feeding glioma containing larvae 10uM and 300uM drugs from the library at early third instar stage, then allow these larvae to grow and mature to the third instar stage (120h of development), and then dissect the brain to study effects on glioma growth and track survival on days 5-7 when other glioma positive larvae die. Here, we present data from our screen on promising drugs from this academic year’s testing focusing on drugs H10 and H11. Once we identify potential glioma inhibitors in the primary screens, we will validate them in secondary screens.
Primary Advisor's Department
Stander Symposium project, College of Arts and Sciences
United Nations Sustainable Development Goals
Good Health and Well-Being
"Possible Cancer Treatment using the Drosophila Glioma Model" (2020). Stander Symposium Projects. 2010.